Eric Brouwer - SQI Diagnostics Chief Scientific Officer
| SQIDFDelisted Stock | USD 0.01 0.00 0.00% |
Executive
Dr. Eric Brouwer, Ph.D., serves as Chief Scientific Officer of the Company. Dr. Brouwer is an accomplished leader in the life sciences sector, with experience in assay design and development, product launch, clinical studies and regulatory submissions. He was most recently the Chief Scientific Officer of Trinity Biotech, ofBray, Ireland, and CEO of Trinity Biotech Swedish subsidiary, Fiomi Diagnostics AB. Trinity Biotech develops, manufactures and markets diagnostics products in autoimmune disease, cardiac markers, infectious disease, and point of care tests. Before working at Trinity, Dr. Brouwer was employed at Abbott Laboratories for 15 years and held progressively senior positions leading Assay Research and Development in Point of Care diagnostics lastly serving as Director, Assay Research and Development since 2017.
| Age | 54 |
| Tenure | 8 years |
| Professional Marks | Ph.D |
| Phone | 416 674 9500 |
| Web | https://www.sqidiagnostics.com |
SQI Diagnostics Management Efficiency
The company has return on total asset (ROA) of (0.9421) % which means that it has lost $0.9421 on every $100 spent on assets. This is way below average. Similarly, it shows a return on equity (ROE) of (12.5407) %, meaning that it generated substantial loss on money invested by shareholders. SQI Diagnostics' management efficiency ratios could be used to measure how well SQI Diagnostics manages its routine affairs as well as how well it operates its assets and liabilities.SQI Diagnostics has accumulated 6.3 M in total debt with debt to equity ratio (D/E) of 4.64, indicating the company may have difficulties to generate enough cash to satisfy its financial obligations. SQI Diagnostics has a current ratio of 0.58, indicating that it has a negative working capital and may not be able to pay financial obligations in time and when they become due. Debt can assist SQI Diagnostics until it has trouble settling it off, either with new capital or with free cash flow. So, SQI Diagnostics' shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like SQI Diagnostics sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for SQI to invest in growth at high rates of return. When we think about SQI Diagnostics' use of debt, we should always consider it together with cash and equity.
Similar Executives
| Showing other executives | EXECUTIVE Age | ||
| Jenny Zheng | Illumina | N/A | |
| Kat Parrella | DarioHealth Corp | N/A | |
| Gael MBA | Volitionrx | 44 | |
| Jacob MBA | Volitionrx | 69 | |
| Kathryne Reeves | Illumina | 55 | |
| Jake MBA | EXACT Sciences | 51 | |
| Jeffrey Novack | Caredx Inc | 42 | |
| Matthew Kupferberg | Enzo Biochem | 58 | |
| Omar MD | DarioHealth Corp | N/A | |
| Jacob Micallef | Volitionrx | 68 | |
| Nicole Berry | Illumina | N/A | |
| Brian Baranick | EXACT Sciences | 47 | |
| Sharon Ballesteros | Volitionrx | N/A | |
| Mary Mooney | DarioHealth Corp | N/A | |
| MD MBA | Natera Inc | N/A | |
| Claudia Levi | DarioHealth Corp | N/A | |
| Phil Grinnell | Natera Inc | N/A | |
| Ankur CPA | Illumina | 48 | |
| Salvatore DVM | Volitionrx | 74 | |
| Ian Cooney | Caredx Inc | N/A | |
| Tomer BenKiki | DarioHealth Corp | 54 | |
Management Performance
| Return On Equity | -12.54 | |||
| Return On Asset | -0.94 |
SQI Diagnostics Leadership Team
Elected by the shareholders, the SQI Diagnostics' board of directors comprises two types of representatives: SQI Diagnostics inside directors who are chosen from within the company, and outside directors, selected externally and held independent of SQI. The board's role is to monitor SQI Diagnostics' management team and ensure that shareholders' interests are well served. SQI Diagnostics' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, SQI Diagnostics' outside directors are responsible for providing unbiased perspectives on the board's policies.
| Andrew Morris, CEO and President and Director | ||
| Russell Peloquin, VP Operations | ||
| Eric Brouwer, Chief Scientific Officer | ||
| CFA CPA, CFO Admin | ||
| Peter Lea, Founder | ||
| Tim McGough, Chief Officer |
SQI Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right pink sheet is not an easy task. Is SQI Diagnostics a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -12.54 | |||
| Return On Asset | -0.94 | |||
| Profit Margin | (2.29) % | |||
| Operating Margin | (1.71) % | |||
| Current Valuation | 34.24 M | |||
| Shares Outstanding | 406.25 M | |||
| Shares Owned By Insiders | 51.02 % | |||
| Shares Owned By Institutions | 24.31 % | |||
| Price To Earning | (2.35) X | |||
| Price To Book | 16.12 X |
Currently Active Assets on Macroaxis
| BTC | Bitcoin | |
| TRX | TRON | |
| BNB | Binance Coin | |
| ADA | Cardano | |
| XRP | XRP |
Check out World Market Map to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in unemployment. You can also try the Portfolio Diagnostics module to use generated alerts and portfolio events aggregator to diagnose current holdings.
Other Consideration for investing in SQI Pink Sheet
If you are still planning to invest in SQI Diagnostics check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the SQI Diagnostics' history and understand the potential risks before investing.
| Stock Screener Find equities using a custom stock filter or screen asymmetry in trading patterns, price, volume, or investment outlook. | |
| Content Syndication Quickly integrate customizable finance content to your own investment portal | |
| Commodity Channel Use Commodity Channel Index to analyze current equity momentum | |
| Transaction History View history of all your transactions and understand their impact on performance | |
| Correlation Analysis Reduce portfolio risk simply by holding instruments which are not perfectly correlated |